Deal Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?
This article was originally published in PharmAsia News
Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales.
You may also be interested in...
Abbott's Piramal Acquisition Is $3.72 Billion Push In Emerging Markets With Established Products
NEW DELHI - Abbott is all set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare, ending months of speculation on which multinational would secure India's fourth-largest pharma compan
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
CNS IPOs Follow Broad Industry Trends
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.